imidazolone and Edema

imidazolone has been researched along with Edema* in 2 studies

Other Studies

2 other study(ies) available for imidazolone and Edema

ArticleYear
New imidazolone derivatives comprising a benzoate or sulfonamide moiety as anti-inflammatory and antibacterial inhibitors: Design, synthesis, selective COX-2, DHFR and molecular-modeling study.
    Bioorganic chemistry, 2020, Volume: 99

    New imidazol-5-one derivatives 12a,b and 12e, f, 14a,b and 16a,b were synthesized and screened for their in vivo anti-inflammatory activity using a standard acute carrageenan-induced rat paw oedema method. All the tested compounds exhibited good anti-inflammatory activity; especially compound 12f which produced the maximum effect of 49.0% compared to the standard drug, celecoxib, (43.1%). The most active anti-inflammatory agents 12a, 12e, and 12f were studied for their interactions with enzyme COX-2 compared to celecoxib. The study showed that, compound 12e exhibited a high selectivity towards COX-2 inhibition with IC

    Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzoates; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Edema; Escherichia coli; Folic Acid Antagonists; Humans; Imidazoles; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Rats; Structure-Activity Relationship; Sulfonamides; Tetrahydrofolate Dehydrogenase

2020
Design, synthesis and in vivo anti-inflammatory activities of 2,4-diaryl-5-4H-imidazolone derivatives.
    Molecules (Basel, Switzerland), 2012, Oct-18, Volume: 17, Issue:10

    A series of 2,4-diaryl-5(4H)-imidazolones were prepared and evaluated for their anti-inflammatory activities. Some selected 2,4-diaryl-5(4H)-imidazolones exhibited excellent anti-inflammatory activity in the carrageenan-induced rat paw edema model. Structure Activity Relationships within the series were studied. The substitution at the N-sulfonamide moiety by a small hydrophilic acetyl group resulted in compounds with superior in vivo anti-inflammatory properties. As expected from their COX-2 selectivity, most of the active compounds lacked gastrointestinal toxicity in vivo in rats after a 3-day treatment of 25 mg/kg/day.

    Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Edema; Imidazoles; Male; Molecular Docking Simulation; Protein Binding; Rats; Structure-Activity Relationship

2012